Blog – Page 13 – PRAIS 2.0

PAHO and Global Affairs Canada initiative strengthens the health of women and adolescents in situations of vulnerability in six countries of the Americas

admin - 15:44, 1 de July de 2025111

PAHO and Global Affairs Canada initiative strengthens the health of women and adolescents in situations of vulnerability in six countries of the Americas

Cristina Mitchell

2 Jul 2025

RSS OPAS

Noncommunicable disease deaths in the Americas have risen 43% since 2000, PAHO report shows

admin - 13:47, 1 de July de 2025154

Noncommunicable disease deaths in the Americas have risen 43% since 2000, PAHO report shows

Cristina Mitchell

2 Jul 2025

rss

Cybersecurity Vulnerabilities with Certain Patient Monitors from Contec and Epsimed: FDA Safety Communication

Murilo Freitas - 04:00, 1 de July de 2025278

The FDA is raising awareness about cybersecurity vulnerabilities with Contec CMS8000 and Epsimed MN-120 patient monitors.

http://www.fda.gov/medical-devices/safety-communications/cybersecurity-vulnerabilities-certain-patient-monitors-contec-and-epsimed-fda-safety-communication

rss

Early Alert: Infusion Pump Software Issue from Baxter

Murilo Freitas - 16:00, 30 de June de 2025108

This communication is part of the Communications Pilot to Enhance the Medical Device Recall Program

http://www.fda.gov/medical-devices/medical-device-recalls/early-alert-infusion-pump-software-issue-baxter

rss

Early Alert: Blood Pump Controller Issue from Abiomed

Murilo Freitas - 04:00, 30 de June de 2025114

This communication is part of the Communications Pilot to Enhance the Medical Device Recall Program

http://www.fda.gov/medical-devices/medical-device-recalls/early-alert-blood-pump-controller-issue-abiomed

rss rss-es rss-pt

Extended-Release Stimulants for ADHD: FDA Drug Safety Communication – FDA Requires Expanded Labeling about Weight Loss Risk in Patients Younger than 6 Years

Murilo Freitas - 04:00, 30 de June de 2025225

The FDA is revising the labeling of all extended-release stimulants indicated to treat attention-deficit/hyperactivity disorder (ADHD) – including certain formulations of amphetamine and methylphenidate – to warn about the risk of weight loss and other adverse reactions (side effects) in patients yo

http://www.fda.gov/safety/medical-product-safety-information/extended-release-stimulants-adhd-fda-drug-safety-communication-fda-requires-expanded-labeling-about

RSS OPAS